Can a heart failure drug ease chest pain from artery spasms?
NCT ID NCT06415227
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether vericiguat, a drug already used for heart failure, can improve blood vessel function in people with vasospastic angina—a type of chest pain caused by spasms in the heart's small arteries, not by blockages. About 57 adults with frequent angina symptoms despite current treatment will receive vericiguat and a placebo in separate 10-week periods. The study measures changes in skin blood flow as a marker of vessel health, aiming to see if the drug can help relax the arteries and reduce symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vericiguat, a drug that stimulates an enzyme to improve blood vessel relaxation
- What this could lead to
- If it works, this could point toward a new treatment option for people with vasospastic angina who continue to have symptoms despite current therapy.
- What could go wrong
- This is a small, early-phase trial with only 57 participants. The drug may cause low blood pressure or dizziness, and its benefits for angina symptoms are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASOSPASTIC ANGINA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC
Amsterdam, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.